As of November 14, 2026, Arcadia Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 6, 2026 to July 2, 2026 (Form 8-K, July 2, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Arcadia Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Arcadia Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-06 to 2026-07-02. Every row below is cited to the filing it comes from, and this page adds each new change as Arcadia Biosciences, Inc. files it.
Also on the record for Arcadia Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 30, 2026 | Stake report, Schedule 13G, by MJL Manager LLC | 15.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| June 26, 2026 | Form D, private offering | $4M sold | Form D page | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 7.75% of the class | 5%+ stakes | Source |
| January 27, 2026 | Form D, private offering | $2.08M sold | Form D page | Source |
| April 1, 2019 | Court case: Bay State Milling Company v. Arcadia Biosciences, Inc., District Court, D. Delaware | — | Court records | Source |
Selling to them or working with them? See who runs Arcadia Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arcadia Biosciences, Inc. and the records around it.
Arcadia Biosciences, Inc. elsewhere on the record
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Form D filing Jan 2026
- Who owns it
Companies that share a holder
- MJL Manager LLC also filed stake reports on 3 other companies: GRI Bio, Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Arcadia Biosciences, Inc.
Get an email when Arcadia Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcadia Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arcadia Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcadia Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-02 | Reported | not named in the filing | 8-K, 2026-07-02 | ||
| 2026-02-06 | Reported | not named in the filing | 8-K, 2026-02-06 |
New leaders reset buying decisions — get the Full Report on Arcadia Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Arcadia Biosciences, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Arcadia Biosciences, Inc., with the record behind each one.
Find candidates like senior executive at Arcadia Biosciences, Inc.Every change, in the filing's words
Reported
Mr. Kawakami resigned as an officer and employee effective September 12, 2025, and his options have expired and terminated.
- On April 30, 2026, Arcadia Biosciences, Inc. (the "Company") filed an amendment to its Annual Report on Form 10-K/A (the "Form 10-K/A") with the Securities and Exchange Commission (the "Commission").
- Instead, the amounts represent aggregate grant date fair value of options granted during 2025 computed in accordance with ASC Topic 718 Stock Compensation.
- The valuation assumptions used in determining such amounts are consistent with those described in Note 13 of the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.
- On May 9, 2025, each of Mr. Schaefer and Mr. Kawakami was granted an option to purchase 12,500 shares of common stock under our 2015 Omnibus Equity Incentive Plan.
- The stock options have a term of ten years and vest over four years, with 25% of the shares subject to the stock options vesting on the first anniversary of the grant date, and an additional 1/36th of the shares vesting each month thereafter, subject to continued service through the applicable vesting dates.
- (2) The amounts shown for 2024 represent amounts earned pursuant to our Executive Incentive Bonus Plan for services in 2024, which were paid in 2025.
- The amounts for 2024 were determined based on a weighting of the achievement of Financial and Individual Goals.
Reported
Their resignation was not because of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, practices or financial statements.
- (b) Resignation of Directors On February 4, 2026, each of Albert D. Bolles, Ph.D., a director and member of the Compensation Committee of the board of directors (the "Board") of Arcadia Biosciences, Inc. (the "Company"), and Deborah Carosella, a director and member of the Compensation Committee and Nominating and Governance Committee of the Board, notified the Company that effective as of February 4, 2026, such person was resigning as a director of the Company and all subsidiaries of the Company of which such person was a director.
- Each person agreed to be available to provide assistance as an advisor.
Arcadia Biosciences, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Arcadia Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
